Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Conclusively, our findings provide supporting evidence for a contributory role of GSTP1 rs4147581 polymorphism in predicting the prognosis of HCC.
|
26260272 |
2016 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Encouragingly, 33.8% of the AFP-negative HCC contained the methylated GSTP1 gene.
|
22536438 |
2012 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals carrying null GSTM1 and GSTP1 Val/Val who received chemotherapy had lower risk of death from HCC than those without chemotherapy.
|
22994742 |
2012 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We conclude that the studied polymorphisms affecting GSTP1, GSTA1 and GSTM3 genes are probably not related to the risk of developing hepatocellular carcinoma in the studied population.
|
17716224 |
2007 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The genes frequently methylated in HCC were APC (81.7%), GSTP1 (76.7%), RASSF1A (66.7%), p16 (48.3%), COX-2 (35%), and E-cadherin (33.3%).
|
14507645 |
2003 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the effects of OCPs exposure on HCC risk are more pronounced amongst GSTP1 (Ile/Val + Val/Val) and GSTP1 promoter methylation subjects than those who were GSTP1 (Ile/Ile) and unmethylated subjects.
|
31731000 |
2020 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, GSTP1 gene polymorphism is not associated with HCC risk.
|
23053942 |
2012 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two SNPs (GSTO2: rs7085725 and GSTP1: rs4147581) were significantly associated with overall survival in HCC patients (P = 0.035 and 0.042, respectively).
|
25892883 |
2015 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals carrying the Ile/Val genotype of GSTP1 had a significant increased risk of HCC (OR of 2.2, 95 % CI 1.143-4.261) and had larger tumor size.
|
27271262 |
2016 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
During the pathogenesis of human hepatocellular carcinoma (HCC), the CpG island encompassing the pi-class glutathione S-transferase gene (GSTP1) becomes hypermethylated.
|
11960994 |
2002 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most frequently methylated TSGs in HCC were: SOCS-1 (65%), GSTP (54%), APC (53%), E-cadherin (49%), and p15 (49%).
|
12937151 |
2003 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AG and GG alleles of GSTP1 gene polymorphisms may be considered as factors increasing the susceptibility to and risk of HCC in Taiwanese aged < or = 57 years.
|
20331903 |
2010 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the meta-analysis suggests that there is little evidence for the association between GSTP1 Ile105Val polymorphism and hepatocellular carcinoma risk.
|
23765758 |
2013 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the studied polymorphisms affecting GSTP1, GSTA1 and GSTM3 genes are probably not related to the risk of developing hepatocellular carcinoma in the studied population.
|
17716224 |
2007 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hypermethylated status of the promoter regions of p16INK4a, RASSF1A, E cadherin, and GSTP1 was observed in 10 (40%), 14 (56%), 6 (24%), and 12 (48%) of 25 patients with hepatocellular carcinoma, respectively.
|
16613325 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that the epigenetic aberrance of promoter CpG island hypermethylation of the GSTP1 gene may contribute to the hepatopathogenesis of HCC and is a potential valuable biomarker for noninvasive disease monitoring and HCC early diagnosis.
|
16527261 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GSTP1 is a largely investigated tissue biomarker in several malignancies such as prostate, breast, lung and hepatocellular carcinoma with good performances especially for diagnostic purposes.
|
29305565 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in GSTM1, GSTP1, and GSTO1 enzymes increase the risk of developing breast cancer and hepatocellular carcinoma.
|
26682223 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Under abnormal conditions the excessive reactive oxygen species generation results in genetic predisposition of various genes (as ADH, ALDH, CYP2E1, GSTT1, GSTP1 and GSTM1) involved in xenobiotic metabolic pathways, associated with susceptibility to different liver related diseases such as fibrosis, cirrhosis and hepatocellular carcinoma.
|
26163595 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, levels of transcript were significantly elevated (up to 16-fold) in total RNA derived from bladder and ureteric carcinomas, with the highest levels of elevation approaching those previously found only for the GST-P gene in experimentally induced rodent hepatocellular carcinomas.
|
3359415 |
1988 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease.
|
14714299 |
2003 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation frequencies of the ten genes examined in HCC were 40.0% for p14 ( ARF ), 60.9% for p15 ( INK4b ), 70.4% for p16 ( INK4a ), 34.8% for p73, 70.4% for GSTP1, 64.3% for MGMT, 13.0% for hMLH1, 59.1% for RARbeta, 82.6% for SOCS-1, and 80.9% for OPCML.
|
20112070 |
2010 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes.
|
9029167 |
1997 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis suggested strong associations between APC, GSTP1 and SOCS1 gene promoter methylation and the risk of HCC, suggesting these to be promising biomarkers for HCC.
|
25853848 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, hypermethylation of some specific, but not all, tumor associated genes may be involved in hepatocarcinogenesis; examination of the methylation status of E-cadherin, GSTP1, P16, and RASSF1A in the plasma samples might have limited usage for HCC diagnosis.
|
18691570 |
2008 |